According to the latest report by IMARC Group, titled “Fibromyalgia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033,” the global fibromyalgia market size is witnessing steady growth. Fibromyalgia refers to a type of chronic disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep disturbances, memory issues, and mood disorders. It is involved in the amplification of pain signals in the brain and spinal cord, leading to an increased sensitivity to pain, but the exact cause of the disease is still unidentified. Fibromyalgia affects people of all ages and backgrounds, although women are more susceptible to developing fibromyalgia compared to men. The symptoms can arise from physical trauma, surgery, infection, or psychological stress, or they can develop gradually over time. Some of the other side effects of fibromyalgia include temporomandibular joint disorders, heightened sensitivity to stimuli, irritable bowel syndrome, anxiety, cognitive difficulties (or fibro fog) and depression. Although a definite cure for the disease is not available, symptom management can be achieved through medications, stress reduction, exercise, relaxation techniques, and combination therapeutics.
Global Fibromyalgia Market Trends:
The global market is majorly driven by a considerable rise in the number of diagnosed fibromyalgia cases among individuals, particularly women. This can be attributed to the increasing prevalence of neurotransmitter imbalances, toxin exposure, and trauma among individuals. In line with this, the augmenting demand for early disease detection and timely treatment interventions along with rising adoption of symptom reliever medications, such as muscle relaxant and anti-inflammatory drugs among individuals, is providing an impetus to the market. Moreover, the emergence of various targeted treatment options, including novel drugs, non-pharmacological interventions, and therapies such as low-level laser therapy (LLLT) are creating lucrative opportunities in the market. In addition to this, the integration of advanced technology in the management of fibromyalgia, such as digital health platforms, telemedicine, and wearable health tracking devices, are impacting the market positively. The market is further fueled by favorable government initiatives, such as expedited drug approval processes and improved reimbursement policies. Apart from this, an enhanced focus on patient-centric care, such as the implementation of integrated care models and personalized multidisciplinary treatment approaches are creating a positive market outlook. Some of the other factors contributing to the market include the growing geriatric population, increasing extensive research and development (R&D) activities focusing underlying causes of fibromyalgia, rising investments by the leading pharmaceutical manufacturers, and the advent of various patient advocacy groups and support organizations.
- Region-wise, the market has been classified into the United States, Germany, France, the United Kingdom, Italy, and Spain, and Japan.
- This research study also offers a thorough overview of late-stage pipeline candidates and currently marketed medications for fibromyalgia.
- The study also offers a thorough overview of the treatment practices for fbromyalgia, the share of specific therapies, and the performance of key market players.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800